126 related articles for article (PubMed ID: 24162837)
21. (177) Lu-5-Fluorouracil a potential theranostic radiopharmaceutical: radiosynthesis, quality control, biodistribution, and scintigraphy.
Rasheed R; Tariq S; Naqvi SA; Gillani SJ; Rizvi FA; Sajid M; Rasheed S
J Labelled Comp Radiopharm; 2016 Aug; 59(10):398-403. PubMed ID: 27444959
[TBL] [Abstract][Full Text] [Related]
22. Prospects of medium specific activity (177) Lu in targeted therapy of prostate cancer using (177) Lu-labeled PSMA inhibitor.
Chakraborty S; Chakravarty R; Shetty P; Vimalnath KV; Sen IB; Dash A
J Labelled Comp Radiopharm; 2016 Jul; 59(9):364-71. PubMed ID: 27264278
[TBL] [Abstract][Full Text] [Related]
23. A novel 177Lu-labeled porphyrin for possible use in targeted tumor therapy.
Das T; Chakraborty S; Sarma HD; Banerjee S; Venakatesh M
Nucl Med Biol; 2010 Jul; 37(5):655-63. PubMed ID: 20610170
[TBL] [Abstract][Full Text] [Related]
24. Estimated human absorbed dose of a new (153)Sm bone seeking agent based on biodistribution data in mice: Comparison with (153)Sm-EDTMP.
Yousefnia H; Zolghadri S
Phys Med; 2015 Nov; 31(7):714-9. PubMed ID: 26095757
[TBL] [Abstract][Full Text] [Related]
25. Multispecies animal investigation on biodistribution, pharmacokinetics and toxicity of 177Lu-EDTMP, a potential bone pain palliation agent.
Máthé D; Balogh L; Polyák A; Király R; Márián T; Pawlak D; Zaknun JJ; Pillai MR; Jánoki GA
Nucl Med Biol; 2010 Feb; 37(2):215-26. PubMed ID: 20152721
[TBL] [Abstract][Full Text] [Related]
26. Complexes of low energy beta emitters 47Sc and 177Lu with zoledronic acid for bone pain therapy.
Majkowska A; Neves M; Antunes I; Bilewicz A
Appl Radiat Isot; 2009 Jan; 67(1):11-3. PubMed ID: 18929490
[TBL] [Abstract][Full Text] [Related]
27. Absorbed dose assessment of (177)Lu-zoledronate and (177)Lu-EDTMP for human based on biodistribution data in rats.
Yousefnia H; Zolghadri S; Jalilian AR
J Med Phys; 2015; 40(2):102-8. PubMed ID: 26170557
[TBL] [Abstract][Full Text] [Related]
28. Comparative studies of 177Lu-EDTMP and 177Lu-DOTMP as potential agents for palliative radiotherapy of bone metastasis.
Chakraborty S; Das T; Sarma HD; Venkatesh M; Banerjee S
Appl Radiat Isot; 2008 Sep; 66(9):1196-205. PubMed ID: 18372188
[TBL] [Abstract][Full Text] [Related]
29. Preparation and preliminary biological evaluation of 177Lu-labelled hydroxyapatite as a promising agent for radiation synovectomy of small joints.
Chakraborty S; Das T; Banerjee S; Sarma HD; Venkatesh M
Nucl Med Commun; 2006 Aug; 27(8):661-8. PubMed ID: 16829766
[TBL] [Abstract][Full Text] [Related]
30. Estimated human absorbed dose of ¹⁷⁷Lu-BPAMD based on mice data: Comparison with ¹⁷⁷Lu-EDTMP.
Yousefnia H; Zolghadri S; Shanehsazzadeh S
Appl Radiat Isot; 2015 Oct; 104():128-35. PubMed ID: 26163291
[TBL] [Abstract][Full Text] [Related]
31. Clinical translation of (177)Lu-labeled PSMA-617: Initial experience in prostate cancer patients.
Das T; Guleria M; Parab A; Kale C; Shah H; Sarma HD; Lele VR; Banerjee S
Nucl Med Biol; 2016 May; 43(5):296-302. PubMed ID: 27150032
[TBL] [Abstract][Full Text] [Related]
32. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
[TBL] [Abstract][Full Text] [Related]
33. 177Lu-labeled cyclic polyaminophosphonates as potential agents for bone pain palliation.
Das T; Chakraborty S; Unni PR; Banerjee S; Samuel G; Sarma HD; Venkatesh M; Pillai MR
Appl Radiat Isot; 2002 Aug; 57(2):177-84. PubMed ID: 12150276
[TBL] [Abstract][Full Text] [Related]
34. Development of a [177Lu]BPAMD labeling kit and an automated synthesis module for routine bone targeted endoradiotherapy.
Meckel M; Nauth A; Timpe J; Zhernosekov K; Puranik AD; Baum RP; Rösch F
Cancer Biother Radiopharm; 2015 Mar; 30(2):94-9. PubMed ID: 25714451
[TBL] [Abstract][Full Text] [Related]
35. Comparative analysis of 11 different radioisotopes for palliative treatment of bone metastases by computational methods.
Guerra Liberal FD; Tavares AA; Tavares JM
Med Phys; 2014 Nov; 41(11):114101. PubMed ID: 25370676
[TBL] [Abstract][Full Text] [Related]
36. Preparation and evaluation of rhenium-188-pamidronate as a palliative treatment in bone metastasis.
Erfani M; Rahmani N; Doroudi A; Shafiei M
Nucl Med Biol; 2017 Jun; 49():1-7. PubMed ID: 28279906
[TBL] [Abstract][Full Text] [Related]
37. In vitro and in vivo characterization of 177Lu-huA33: a radioimmunoconjugate against colorectal cancer.
Almqvist Y; Steffen AC; Tolmachev V; Divgi CR; Sundin A
Nucl Med Biol; 2006 Nov; 33(8):991-8. PubMed ID: 17127172
[TBL] [Abstract][Full Text] [Related]
38. Preparation and evaluation of Lu-(177) phytate Complex for Radiosynovectomy.
Yousefnia H; Jalilian AR; Zolghadri S
World J Nucl Med; 2014 Jan; 13(1):22-7. PubMed ID: 25191108
[TBL] [Abstract][Full Text] [Related]
39. Preclinical evaluation of (177)lu-nimotuzumab: a potential tool for radioimmunotherapy of epidermal growth factor receptor-overexpressing tumors.
Vera DR; Eigner S; Beran M; Henke KE; Laznickova A; Laznicek M; Melichar F; Chinol M
Cancer Biother Radiopharm; 2011 Jun; 26(3):287-97. PubMed ID: 21711096
[TBL] [Abstract][Full Text] [Related]
40. Preparation and biological evaluation of (177)Lu conjugated PR81 for radioimmunotherapy of breast cancer.
Salouti M; Babaei MH; Rajabi H; Rasaee Mj
Nucl Med Biol; 2011 Aug; 38(6):849-55. PubMed ID: 21843781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
